Results 251 to 260 of about 89,590 (297)
Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 1990 G, Gadeholt, I, Aursnes
openaire +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Survey of Anesthesiology, 1993
To assess the prevalence of cough as a side effect of angiotensin-converting enzyme inhibitor antihypertensive therapy, we reviewed 300 consecutive patient charts from a private practice and 200 consecutive patient charts from a university-based referral center for hypertension.
S R, Simon +3 more
openaire +4 more sources
To assess the prevalence of cough as a side effect of angiotensin-converting enzyme inhibitor antihypertensive therapy, we reviewed 300 consecutive patient charts from a private practice and 200 consecutive patient charts from a university-based referral center for hypertension.
S R, Simon +3 more
openaire +4 more sources
Angiology, 1994
Probably the most common and irritating side effect of angiotensin-converting enzyme (ACE) inhibitors is cough. In this retrospective study the incidence of cough was investigated in 1113 patients with arterial hypertension who were receiving ACE inhibitors alone or in combination with other antihypertensive agents.
POSTACI, N +3 more
openaire +3 more sources
Probably the most common and irritating side effect of angiotensin-converting enzyme (ACE) inhibitors is cough. In this retrospective study the incidence of cough was investigated in 1113 patients with arterial hypertension who were receiving ACE inhibitors alone or in combination with other antihypertensive agents.
POSTACI, N +3 more
openaire +3 more sources
ACE inhibitors and proteinuria
Pharmacy World and Science, 1996This review discusses the clinical consequences of urinary protein loss and the effects of inhibitors of the angiotensin converting enzyme (ACE) on this clinical finding. Proteinuria appears to be an important risk factor for renal function deterioration and for cardiovascular mortality.
R T, Gansevoort +2 more
openaire +2 more sources
ACE-inhibitors and atherosclerosis
European Journal of Epidemiology, 1992The involvement of the circulating and local renin-angiotensin system in atherosclerotic process has been hypothesized on the basis of experimental data showing presence and specific actions of the components of this system in the vascular wall. In particular, angiotensin II may participate in well known events in atherogenesis as the control of smooth
E, Ambrosioni +3 more
openaire +2 more sources
Angiology, 1991
As the population with hypertension becomes older, it is important to determine the properties of angiotensin-converting enzyme (ACE) inhibitors in the elderly. The pharmacokinetics and efficacy of captopril, enalapril, and a new once-daily ACE inhibitor, quinapril for the treatment of hypertension in young and elderly patients are reviewed, and the ...
E L, Posvar, A J, Sedman
openaire +2 more sources
As the population with hypertension becomes older, it is important to determine the properties of angiotensin-converting enzyme (ACE) inhibitors in the elderly. The pharmacokinetics and efficacy of captopril, enalapril, and a new once-daily ACE inhibitor, quinapril for the treatment of hypertension in young and elderly patients are reviewed, and the ...
E L, Posvar, A J, Sedman
openaire +2 more sources
Nitrendipine and ACE Inhibitors
Journal of Cardiovascular Pharmacology, 1988There is evidence from several studies of the clinical usefulness of an antihypertensive regimen combining a calcium antagonist and an angiotensin converting enzyme (ACE) inhibitor. The mechanisms of this mutual potentiation between agents of these two classes are probably numerous.
openaire +2 more sources
Reactions Weekly
Abstract ACE inhibitors were first introduced because of their vasodilatory properties. It is now understood that the beneficial effects arise from the antagonism of the renin–angiotensin–aldosterone system. ACE inhibitors are first-line agents for all patients with HFrEF—this is also true in patients with asymptomatic LVSD.
Roy S. Gardner +3 more
+4 more sources
Abstract ACE inhibitors were first introduced because of their vasodilatory properties. It is now understood that the beneficial effects arise from the antagonism of the renin–angiotensin–aldosterone system. ACE inhibitors are first-line agents for all patients with HFrEF—this is also true in patients with asymptomatic LVSD.
Roy S. Gardner +3 more
+4 more sources